EBX-102 demonstrated proof-of-principle across multiple microbiome assessments, inflammatory biomarkers and clinical assessments, supporting its cont ...

Detailed price information for Akero Therapeutics Inc (AKRO-Q) from The Globe and Mail including charting and trades.

Carlsbad, CA, Nov. 07, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for ...

Personalized energy expenditure data significantly improved weight loss outcomes in patients with obesity, enhancing ...

Amgen (AMGN) and AstraZeneca (AZN) announced top-line results from the Phase 3 WAYPOINT trial in patients with chronic rhinosinusitis with ...

AstraZeneca and Amgen's Phase 3 trial data shows Tezspire significantly reduces nasal polyps and congestion in patients with chronic rhinosinusitis with nasal polyps.

Cash, cash equivalents, and marketable securities of $360.1 million at Q3 2024 - CARLSBAD, Calif., Nov. 7, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical ...

AM003 is a first-in-class functional oligonucleotide in development for the treatment of solid tumorsFirst –in-human, monotherapy dose-escalation ...

Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to ...

- Interim phase 1 clinical trial update reveals the clinical potential of the tumor-activated IL-12 prodrug WTX-330, with favorable tolerability profile and encouraging efficacy signals - ...

Patients with EGFR-mutant non-small cell lung cancer who are TKI-naïve benefited from receiving the Cyramza-Tagrisso combination versus Tagrisso alone.

In patients with migraine, erenumab was safe and tolerable and effectively reversed migraine deterioration during treatment pauses.